Trends in the Susceptibility of Clinically Important Resistant Bacteria to Tigecycline: Results from the Tigecycline In Vitro Surveillance in Taiwan Study, 2006 to 2010

被引：36

作者：

Chen, Yen-Hsu ^{[3
,4
]}

Lu, Po-Liang ^{[3
,4
]}

Huang, Cheng-Hua ^{[5
]}

Liao, Chun-Hsing ^{[6
]}

Lu, Chin-Te ^{[7
]}

Chuang, Yin-Ching ^{[8
]}

Tsao, Shih-Ming ^{[9
,10
]}

Chen, Yao-Shen ^{[11
,12
,13
]}

Liu, Yung-Ching ^{[11
,12
,13
]}

Chen, Wei-Yu ^{[14
]}

Jang, Tsrang-Neng ^{[14
]}

Lin, Hsiu-Chen ^{[15
]}

Chen, Chih-Ming ^{[16
]}

Shi, Zhi-Yuan ^{[17
]}

Pan, Sung-Ching ^{[18
,19
]}

Yang, Jia-Ling ^{[18
,19
]}

Kung, Hsiang-Chi ^{[18
,19
]}

Liu, Chun-Eng ^{[20
]}

Cheng, Yu-Jen ^{[20
]}

Liu, Jien-Wei ^{[21
]}

Sun, Wu ^{[22
]}

Wang, Lih-Shinn ^{[23
]}

Ko, Wen-Chien ^{[24
]}

Yu, Kwok-Woon ^{[25
]}

Chiang, Ping-Cherng ^{[26
]}

Lee, Ming-Hsun ^{[26
]}

Lee, Chun-Ming ^{[27
]}

Hsu, Gwo-Jong ^{[28
]}

Hsueh, Po-Ren ^{[1
,2
]}

机构：

[1] Natl Taiwan Univ Coll Med, Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan

[2] Natl Taiwan Univ Coll Med, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[3] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan

[4] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan

[5] Cathay Gen Hosp, Dept Internal Med, Div Infect Dis, Taipei, Taiwan

[6] Far Eastern Mem Hosp, Dept Internal Med, Infect Dis Sect, Taipei, Taiwan

[7] Lotung Poh Ai Hosp, Dept Internal Med, Infect Dis Sect, Yilan, Taiwan

[8] Chi Mei Med Ctr, Dept Internal Med, Tainan, Taiwan

[9] Chung Shan Med Univ, Inst Microbiol & Immunol, Dept Internal Med, Infect Dis Sect, Taichung, Taiwan

[10] Univ Hosp, Taichung, Taiwan

[11] Taipei Med Univ, Sch Med, Taipei, Taiwan

[12] Taipei Med Univ, Shuang Hosp, Infect Dis Sect, Taipei, Taiwan

[13] Kaohsiung Vet Gen Hosp, Dept Internal Med, Infect Dis Sect, Kaohsiung, Taiwan

[14] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Infect Dis Sect, Taipei, Taiwan

[15] Taipei Med Univ, Coll Med, Sch Med, Dept Pediat, Taipei, Taiwan

[16] Tungs Taichung MetroHarbor Hosp, Dept Internal Med, Infect Dis Sect, Taichung, Taiwan

[17] Taichung Vet Gen Hosp, Infect Dis Sect, Dept Internal Med, Taichung, Taiwan

[18] Natl Taiwan Univ Hosp Yun Lin Branch, Dept Internal Med, Infect Dis Sect, Yunlin, Taiwan

[19] Natl Taiwan Univ Hosp, Dept Internal Med, Yunlin, Taiwan

[20] Changhua Christian Hosp, Dept Internal Med, Infect Dis Sect, Changhua, Taiwan

[21] Kaohsiung Chang Gung Mem Hosp, Chang Gung Med Coll, Div Infect Dis, Dept Internal Med, Kaohsiung, Taiwan

[22] Pao Chien Hosp, Dept Infect Control, Pingtung, Taiwan

[23] Buddhist Tzu Chi Gen Hosp, Dept Internal Med, Infect Dis Sect, Hualien, Taiwan

[24] Natl Cheng Kung Univ Med Coll & Hosp, Dept Med, Tainan, Taiwan

[25] Taipei Vet Gen Hosp, Div Infect Dis, Dept Internal Med Pathol & Lab Med, Taipei, Taiwan

[26] Chang Gung Med Fdn Linkou Branch, Dept Internal Med, Div Infect Dis, Tao Yuan, Taiwan

[27] Mackay Mem Hosp, Dept Internal Med, Infect Dis Sect, Taipei, Taiwan

[28] Ditmanson Med Fdn Chiayi Christian Hosp, Dept Internal Med, Infect Dis Sect, Chiayi, Taiwan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2012年 / 56卷 / 03期

关键词：

ANTIMICROBIAL RESISTANCE; ACINETOBACTER; TRIAL; ENTEROBACTERIACEAE; PNEUMONIAE; ACRAB; PART;

D O I：

10.1128/AAC.06053-11

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, a nationwide, prospective surveillance during 2006 to 2010, collected a total of 7,793 clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA) (n = 1,834), penicillin-resistant Streptococcus pneumoniae (PRSP) (n = 423), vancomycin-resistant enterococci (VRE) (n = 219), extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (n = 1,141), ESBL-producing Klebsiella pneumoniae (n = 1,330), Acinetobacter baumannii (n = 1,645), and Stenotrophomonas maltophilia (n = 903), from different specimens from 20 different hospitals in Taiwan. MICs of tigecycline were determined following the criteria of the U.S. Food and Drug Administration (FDA) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011). Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC90, 0.03 mu g/ml), and only one MRSA isolate (MIC90, 0.5 mu g/ml) and three VRE isolates (MIC90, 0.125 mu g/ml) were nonsusceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC90, 0.5 mu g/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC90, 2 mu g/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility rate for A. baumannii (MIC90, 4 mu g/ml) decreased from 80.9% in 2006 to 55.3% in 2009 but increased to 73.4% in 2010. A bimodal MIC distribution was found among carbapenem-susceptible A. baumannii isolates, and a unimodal MIC distribution was found among carbapenem-nonsusceptible A. baumannii isolates. In Taiwan, tigecycline continues to have excellent in vitro activity against several major clinically important drug-resistant bacteria, with the exception of A. baumannii.

引用

页码：1452 / 1457

页数：6

共 21 条

[1] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].

Boucher, Helen W. ;

Talbot, George H. ;

Bradley, John S. ;

Edwards, John E., Jr. ;

Gilbert, David ;

Rice, Louis B. ;

Scheld, Michael ;

Spellberg, Brad ;

Bartlett, John .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12

[2] Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST) [J].

Bouchillon, Sam K. ;

Iredell, Jonathan R. ;

Barkham, Timothy ;

Lee, Kyungwon ;

Dowzicky, Michael J. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (02) :130-136

[3] Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease [J].

Cai, Yun ;

Wang, Rui ;

Liang, Beibei ;

Bai, Nan ;

Liu, Youning .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (03) :1162-1172

[4]

Chen WY, 2009, J MICROBIOL IMMUNOL, V42, P317

[5] Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria [J].

Chen, Yen-Hsu ;

Hsueh, Po-Ren ;

Badal, Robert E. ;

Hawser, Stephen P. ;

Hoban, Daryl J. ;

Bouchillon, Samuel K. ;

Ni, Yuxing ;

Paterson, David L. .

JOURNAL OF INFECTION, 2011, 62 (04) :280-291

[6]

Clinical and Laboratory Standards Institute, 2011, M100S20 CLIN LAB STA

[7] The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs [J].

Cosgrove, SE .

CLINICAL INFECTIOUS DISEASES, 2006, 42 :S82-S89

[8] Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial [J].

Darabi, Ali ;

Hocquet, Didier ;

Dowzicky, Michael J. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2010, 67 (01) :78-86

[9] Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009 [J].

Dowzicky, Michael J. ;

Chmelarova, Eva .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (06) :562-566

[10] The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008) [J].

Farrell, David J. ;

Turnidge, John D. ;

Bell, Jan ;

Sader, Helio S. ;

Jones, Ronald N. .

JOURNAL OF INFECTION, 2010, 60 (06) :440-451

← 1 2 3 →